Výsledky vyhledávání - "M. D. Pescovitz"

An Assessment of Herpesvirus Co-infections in Patients with CMV Disease: Correlation with Clinical and Virologic Outcomes

Autor: A, Humar, A, Asberg, D, Kumar, A, Hartmann, G, Moussa, A, Jardine, H, Rollag, H, Mouas, C G, Gahlemann, M D, Pescovitz, Michael, Zakliczynsk

Publikováno v: American Journal of Transplantation. 9:374-381

The effect of herpesvirus co-infections (HHV-6, HHV-7) on cytomegalovirus (CMV) disease and its response to therapy is unknown. We prospectively analyzed herpesvirus co-infections in transplant recipients with CMV disease. All patients received 3 wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9fd25a0a732d18a40116764f59be07
https://doi.org/10.1111/j.1600-6143.2008.02501.x

Zobrazit plný text záznamu

Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients

Autor: M D, Pescovitz, R B, Ettenger, C F, Strife, J R, Sherbotie, S E, Thomas, S, McDiarmid, S, Bartosh, J, Ives, M R, Bouw, J, Bucuvalas

Publikováno v: Transplant infectious disease : an official journal of the Transplantation Society. 12(3)

In an open-label, prospective, pharmacokinetic assessment, we evaluated total drug exposure (area under the curve [AUC]) of intravenous (IV) ganciclovir (GCV) and oral (p.o.) valganciclovir when normalized for body surface area (BSA) in pediatric liv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::afa6149c0add58f9fd5ece20258ad478
https://pubmed.ncbi.nlm.nih.gov/20002356

Zobrazit plný text záznamu

Central pontine myelinolysis following orthotopic liver transplant: association with cyclosporine toxicity

Autor: R. S. Filo, S. B. Leapman, L. Lumeng, M. D. Pescovitz, M. H. Kabeer, Rahul M. Jindal, M. L. Milgrom

Publikováno v: Postgraduate Medical Journal. 71:239-241

Central pontine myelinolysis can occur after orthotopic liver transplantation leading to high mortality and serious morbidity. In our case, central pontine myelinolysis was associated with wide fluctuations in cyclosporine levels during an episode of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::414d30e82d3bb1ae084a271fb9e476e1
https://doi.org/10.1136/pgmj.71.834.239

Zobrazit plný text záznamu

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

Autor: G L, Bumgardner, I, Hardie, R W, Johnson, A, Lin, B, Nashan, M D, Pescovitz, E, Ramos, F, Vincenti

Publikováno v: Transplantation. 72(5)

Daclizumab (Zenapax, Roche Pharmaceuticals), a humanized monoclonal antibody directed against the alpha chain of the interleukin 2 receptor, has been shown to reduce the incidence of acute rejection at 6 months after renal transplantation in two phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aa4d33cde1eccafe72d918fe55c4d288
https://pubmed.ncbi.nlm.nih.gov/11571447

Zobrazit plný text záznamu

Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients

Autor: M D, Pescovitz

Publikováno v: Transplant infectious disease : an official journal of the Transplantation Society. 1

The pivotal trial demonstrating efficacy of oral ganciclovir in preventing cytomegalovirus (CMV) disease following organ transplantation was conducted in liver transplant recipients, in whom the rate of CMV disease was reduced from 19% to 5%. Pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b5523f9b5e270977237e245ef2bef96
https://pubmed.ncbi.nlm.nih.gov/11565585

Zobrazit plný text záznamu

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

Autor: J M, Kovarik, M D, Pescovitz, H W, Sollinger, B, Kaplan, C, Legendre, K, Salmela, B K, Book, C, Gerbeau, D, Girault, K, Somberg

Publikováno v: Clinical transplantation. 15(2)

Pharmacokinetic sampling was performed in two multicenter trials in which basiliximab (anti-CD25 monoclonal antibody) was administered with triple immunosuppression consisting of cyclosporine microemulsion, corticosteroids, and either azathioprine or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a1b8fcca6157e4a9d8cb0ab09ab192f4
https://pubmed.ncbi.nlm.nih.gov/11264639

Zobrazit plný text záznamu

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics

Autor: M D, Pescovitz, D, Conti, J, Dunn, T, Gonwa, P, Halloran, H, Sollinger, S, Tomlanovich, S, Weinstein, S, Inokuchi, B, Kiberd, D, Kittur, R M, Merion, D, Norman, A, Shoker, R, Wilburn, A J, Nicholls, S, Arterburn, E, Dumont

Publikováno v: Clinical transplantation. 14(3)

An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9d73bfeadc97809deb1aa53ef71cf991
https://pubmed.ncbi.nlm.nih.gov/10831074

Zobrazit plný text záznamu

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

Autor: B D, Kahan, B A, Julian, M D, Pescovitz, Y, Vanrenterghem, J, Neylan

Publikováno v: Transplantation. 68(10)

The novel agent sirolimus (SRL; Rapamune; rapamycin) inhibits the immune response by a mechanism distinct from those of calcineurin antagonists or antimetabolites. This randomized, controlled, multicenter, single blind, phase II trial examined the co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2cb302a1814cd6482d59f36296c61936
https://pubmed.ncbi.nlm.nih.gov/10589950

Zobrazit plný text záznamu

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group

Autor: P, Hengster, M D, Pescovitz, D, Hyatt, R, Margreiter

Publikováno v: Transplantation. 68(2)

Daclizumab is a newly developed humanized anti-IL-2 receptor monoclonal antibody. We describe the effect of adding daclizumab to conventional dual or triple cyclosporine A immunosuppressive therapy on the incidence and nature of cytomegalovirus (CMV)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::911b58a79cfd9d39dd55729fb9b2260a
https://pubmed.ncbi.nlm.nih.gov/10755575

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání